Published: 05 September 2023
Researchers at St George’s, University of London have discovered a technique that can kill skin cancer cells whilst minimising damage to healthy cells.
Fifth most common cancer in the UK
Melanoma skin cancer is the fifth most common cancer in the UK. It’s anticipated that the number of people with skin cancer is likely to continue to rise with recent estimates suggesting cases will increase 50 per cent in the next 20 years.
Early diagnoses and treatments for skin cancer have been key to reduce the number of deaths, but it’s vital that new therapies are developed to neutralise melanomas that have metastasized and spread from the skin to other parts of the body.
Targeting a 'molecular switch'
Professor Dot Bennett and her team worked on a protein known as p16, which acts like a ‘molecular switch’. Normally, it causes cells to stop dividing before they grow out of control and is known for its ability to suppress tumour development. But when this switch is broken, it allows cells to grow out of control and become cancer.
They made a series of changes to a small, active section of p16 – called a p16-related peptide – including a change enabling it to enter cells. They added it to melanoma skin cancer cells in the laboratory to see if it would stop them from dividing. The peptide was also tested on normal skin pigment cells and other skin cells called fibroblasts.
Cancer cells wiped out but more research needed
“We tried the p16 peptide on three lines made up of metastatic melanoma cells. All of those were nicely wiped out, yet it did little harm to the normal cells, which is very promising. We were very surprised at its effectiveness and although a great deal of extra work needs to be done before we can think of using this on human patients, it is very encouraging.”
- Prof Dot Bennett, Professor of Cell Biology at the Molecular and Clinical Sciences Research Institute, St George’s, University of London -
The research was funded by Cancer Research UK, the British Skin Foundation and Age UK, and published in the journal Biology Open.
Chief Executive of Cancer Research UK, Michelle Mitchell, said: “More people than ever are surviving melanoma skin cancer, but there remains a critical gap in survival between people diagnosed at early stages compared to those diagnosed later.
“One of the best strategies to address that gap is to find new treatments which attack cancer, whilst minimising harm to healthy cells. p16-related peptide could offer a promising new approach for those patients diagnosed with metastatic disease, where options for treatment are currently more limited.”
Adil Sheraz, Consultant Dermatologist & British Skin Foundation spokesperson added: “This research is an exciting development towards treating melanoma, the most lethal form of skin cancer. The protein p16-related peptide preferentially targets melanoma cells, preserving fibroblasts – which play a vital part in skin repair and regeneration – and causing minimal damage to other cells. Whilst further research is needed, this has the potential for much more favourable outcomes for melanoma patients.”
Further research is now needed to test the p16-related peptide on other types of healthy skin cells and to determine how the cancer-killing mechanism is triggered.
Learn more about research in the Molecular and Clinical Sciences Institute